Botox Battle Rages With Upstart Evolus Backed by Dermatologists
- Doctors ask U.S. agency to let Evolus continue Jeuveau imports
- Abbvie’s Allergan says Jeuveau developed with stolen secrets
Photographer: Patrick T. Fallon/Bloomberg
This article is for subscribers only.
Evolus Inc. is getting support for its legal battle with AbbVie Inc.’s Allergan over a rival to the Botox wrinkle treatment from dermatologists tired of an “800-pound gorilla” controlling the beauty market.
More than four dozen dermatologists have written to the U.S. International Trade Commission, asking it to allow Botox rival Jeuveau to stay on the U.S. market. A trade judge in July recommended a 10-year ban on imports of Korean-made Jeuveau, saying it was created using a stolen formula.